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ABSTRACT
The significant increase in antimicrobial resistance over the past few years is
a serious global public health concern, particularly as the development of new
antimicrobial agents had been slow for many years. Infections with resistant
organisms are associated with poor clinical outcomes and higher cost burdens.
Determining antimicrobial resistance patterns can help identify problem areas and
modify treatment practices to improve clinical outcomes. Additionally, identifying
adjunctive therapies can also help improve clinical outcomes among infected
patients. The objectives, hypotheses, methods and results of this dissertation are
threefold:

Manuscript 1: The objective was to analyze antimicrobial resistance trends in
E. faecalis and E. faecium between 2003 and 2015 in five acute care facilities of the
Veterans Affairs New England Healthcare System as antimicrobial resistance
patterns among Enterococcus have changed over the past decade. Using a multicenter ecologic study design, we evaluated antimicrobial resistance patterns for blood
and urine cultures of enterococci. In E. faecium urine cultures, a decline in gentamicin
resistance, as well as a small decease in vancomycin resistance were observed.
Enterococcus resistance towards ampicillin, linezolid, and tetracycline was stable
over the study period. Daptomycin resistance did not emerge over the study period.

Manuscript 2: The objective was to evaluate the impact of statin exposure on
clinical outcomes, including inpatient mortality and length of inpatient stay, among
bacteremic patients. The hypothesis was that statin use would be associated with
positive clinical outcomes compared to non-statin use. We conducted a retrospective
cohort study using the deidentified Optum ClinformaticsTM (OptumInsight, Eden

Prairie, MN) with matched Premier Hospital data (October 2009-March 2013). Our
retrospective cohort study observed lower mortality for incident users and prevalent
users continuing statin use during admission. Though non-significant in incident
users, the point estimate was similar to that observed in other studies.

Manuscript 3: The objective was to identify a statin therapy duration among
pre-defined baseline statin users at which use of statins minimizes the risk of inpatient
mortality among bacteremic patients. The hypothesis was that a certain minimum
duration of statin use during the hospitalization would improve survival. A casecontrol design was used to test this hypothesis using the Optum ClinformaticsTM with
matched Premier Hospital data (October 2009-March 2013). Classification and
regression tree analysis was conducted among cases and controls matched on
disease risk scores. Among matched pairs of cases and controls with at least 90 days
of pre-admission statin use, the continuation of statin use during admission for at
least 2 days provided a better survival benefit among bacteremic patients.
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PREFACE
This dissertation is written in the manuscript format, and is comprised of three
manuscripts, which evaluated (1) antimicrobial resistance patterns in Enterococcus
pathogens, (2) the impact of statin exposure on clinical outcomes in bacteremic
patients, and (3) optimal statin adjunctive therapy duration among
bacteremic patients.
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1.1 Abstract
Enterococcus faecalis and E. faecium antibiotic resistance trends from 2003-2015 in
clinical blood and urine cultures were evaluated among the New England Veteran
Affairs hospitals using generalized linear mixed models. Over 10,000 unique isolates
were included. In E. faecium urine cultures, a decrease in gentamicin resistance was
noted (mean 2.9%/year). Vancomycin resistance slightly decreased in E. faecium
urine cultures (mean 0.1%/year). Daptomycin resistance did not emerge, while
ampicillin, linezolid, and tetracycline resistance remained stable over the study
period.
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1.2 Introduction
Antimicrobial resistance among Enterococcus has been increasing in the
United States (U.S.) over the past several years.1,2 These bacteria have developed
resistance to nearly every antibiotic used for treatment.2,3 Further, the occurrence of
resistance in enterococci to comparatively new antibiotics, such as daptomycin4 and
tigecycline,5 as well as developing resistance to adjunctive therapies, such as
gentamicin, is a substantial public health concern.2 Infections with resistant organisms
are associated with poor clinical outcomes,6 and increased health and cost burdens.7
As antibiotic resistance changes, enterococcal infections are becoming more difficult
to treat, potentially leading to the administration of inappropriate empiric therapies8,9
that could increase mortality risk.10 Vancomycin resistance in enterococci (VRE) has
increased extensively in the past few decades, and is considered a "serious threat" as
each year, 20,000 (or 30%) Enterococcus healthcare-associated infections are
vancomycin-resistant causing an estimated 1,300 deaths in the U.S.11 With the
changing epidemiology of infections,12,13 frequent review of resistance, with respect to
historical patterns, is crucial to identifying problems with resistance and response to
such changes, such as modifications to treatment practices.14 This study aimed to
describe antimicrobial resistance trends of E. faecalis and E. faecium in a large,
regional healthcare system.

1.3 Methods
A multi-center ecologic study design was used to evaluate annual antibiotic
susceptibility from 2003 to 2015 among blood and urine isolates from five New
England Veteran Affairs (VA) Medical Centers (Boston MA, Providence RI, Togus
ME, White River Junction VT, and West Haven CT), based on Clinical and Laboratory
Standards Institute (CLSI) guidance15,16. Changes in the percent resistance over the

3

study period were assessed with generalized linear mixed models (GLMM). GLMM
accounts for the clustered nature of the study design by incorporating correlations
among responses through the inclusions of random effects in the linear predictor
and/or by modeling the correlations among the data directly.16 Generalized models
are commonly used when response variables have error distribution models other
than a normal distribution.16 The general form of the model is: y

The

events/trial syntax (number resistant/number of isolates tested for a given antibiotic)
served as the response variable and the 'year' functioned as the independent
categorical variable. The binomial distribution and logit link were used for all GLMM
models due to the event/trial syntax of a dependent variable. To account for the
interdependence of samples within the five facilities (clusters), 'facility' was included
as a random effect in the GLMM models. Significance was defined as an α (alpha) of
0.05 and all models were run in SAS 9.4 (SAS Institute, Cary, NC, USA).

1.4 Results
Over the thirteen-year study period, 10,257 unique enterococci isolates were
extracted from blood and urine culture sites, of which 86.7% (n=8,894) were E.
faecalis [blood=585 (6.6%), urine=8,309 (93.4%)] and 13.3% (n=1,363) were E.
faecium [blood=246 (18.0%), urine=1,117 (82.0%)].

E. faecalis resistance remained steady between 2003 and 2015, except for
resistance to tetracycline. We observed a significant increase in the annualized
modeled change in tetracycline resistance for E. faecalis urine cultures (0.4%/year,
mean isolates tested per year [mean n]=370, % resistance in 2003 and 2015
[resistance y03]=66.1%, [y15]=70.7%, p<0.01, Figure 1). Vancomycin resistance in E.
faecalis remained low, and decreased non-significantly by an average 0.43%/year in
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blood (mean n=45, resistance y03=5.1%, y15=0.0%, p=0.67) and 0.16%/year in urine
cultures (mean n=639, resistance y03=5.1%, y15=3.2%, p=0.26). Resistance to
ampicillin, a commonly used therapy for E. faecalis infections,17,18 remained low and
stable in both blood (resistance all years, <3.1%) and urine (resistance all years,
<1.4%). Linezolid resistance was also low and stable in E. faecalis urine cultures
(mean n=112, resistance y03=1.9%, y15=2.3%, p=1.00).

In E. faecium urine isolates, a small annual decrease of 0.10%/year in
vancomycin resistance was observed (mean n=86, resistance y03=68.7%,
y15=67.3%, p=0.01, Figure 2). While the trend was statistically significant, the clinical
relevance of a 1.20% decrease in resistance over the study period may be negligible.
Conversely, vancomycin resistance in E. faecium blood isolates increased nonsignificantly by 1.59%/year (mean n=19, resistance y03=63.3%, y15=82.4%, p=0.70).
In E. faecium urine cultures, a statistically significant decrease in gentamicin
resistance was observed (2.93%/year, mean n=13, resistance y03=35.1%,
y15=0.0%, p<0.0001). Tetracycline resistance increased significantly in blood
(5.56%/year, mean n=11, resistance y03=50.0%, y15=100.0%, p<0.01) and urine
isolates (0.21%/year, mean n=54, resistance y03=73.1%, y15=75.6%, p=0.01).

Resistance towards ampicillin remained high, but stable in E. faecium blood
(mean 1.40%/year decrease, mean n=19, resistance y03=98.8%, y15=80.0%,
p=0.81) and urine (mean 0.68%/year decrease, mean n=80, resistance y03=95.1%,
y15=86.9%, p=0.07) cultures. Linezolid resistance in E. faecium was observed, but
remained low and non-significantly decreased by 0.53%/year in urine (mean n=55,
resistance y03=7.9%, y15=1.5%, p=0.69). We did not observe any daptomycin-
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resistant isolates in either E. faecalis (0/552) or E. faecium (0/195) from 2007 when
daptomycin susceptibility testing began.

1.5 Discussion
In this ecologic study conducted in New England VA Medical Centers between
2003 and 2015, antibiotic resistance in enterococci was mostly stable. Decreased
vancomycin resistance in E. faecium blood isolates was reported in an Italian study,
with resistance dropping from 24.1% in 2003 to 4.3% in 2009, and remaining between
4-6% until 2013.19 A report from the SENTRY Antimicrobial Surveillance Program
(2011–2014) among 21 Latin American medical centers (11 nations) observed a
vancomycin resistance rate of 50.3% in E. faecium and 2.3% in E. faecalis.20
Vancomycin resistance in E. faecium was high in our study, however, we observed a
small, but significant decrease in urine isolates which could be a result of successful
infection control strategies and antimicrobial stewardship activities.21 In E. faecalis,
vancomycin resistance was low and decreased non-significantly in both culture sites.
This findings are positive considering the spread of VRE over the past two decades.22

Other encouraging results besides decreasing vancomycin resistance in E.
faecalis, were the stable resistance rates or small decreases in resistance rates to
conventional therapies,17 such as ampicillin, in E. faecium. Daptomycin has been
approved by the Food and Drug Administration (FDA) to treat VRE due to in-vitro
bactericidal activity against VRE,23 however, the emergence of daptomycin resistance
for E. faecium has been observed recently.4,24 Another positive finding in our study
was the non-emergence of daptomycin resistance in enterococci blood and urine
cultures.
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An increasing trend of E. faecium resistance to ampicillin, which is used for
the treatment of VRE faecalis and susceptible E. faecium, was reported in 28
hospitals in Thailand, growing from 52.0% in 2000 to 84.1% in 2005.26 Ampicillin
resistance in E. faecium is high,27-29 especially in VRE faecium.30 Similar to the
current literature, ampicillin resistance rates in E. faecium remained high (>75%) in
our study, despite non-significant decreases in both urine and blood cultures.
Compared to the high ampicillin resistance in E. faecium, VRE faecalis strains usually
remain susceptible to ampicillin.30 We also observed low ampicillin resistance in E.
faecalis, which remained stable over the study period.

Tetracycline resistance in E. faecium increased in urine and blood cultures.
While tetracycline exhibits clinically significant anti-enterococcal activity, it is generally
considered a second-line agent and is seldom used for enterococci treatment.18 As a
result, susceptibility testing against this antibiotic declined, and therefore, the
tetracycline resistance was only tested in few blood isolates after 2010 (n<3),
resulting in larger differences in percent resistance year to year. Tetracycline
resistance increases were not as large in years when more isolates were tested.

Linezolid resistance was observed in 4 of 5 facilities in our study, but the rates
remained stable and low (<3%) over the study period. Linezolid is approved by FDA
for the treatment of VRE faecium infections31 and it remains a crucial therapy for
linezolid-susceptible isolates of both E. faecalis and E. faecium. Linezolid resistance
is usually low in enterococci and was rarely reported in VRE until the past few years,
however, recent VRE outbreaks have resulted in higher rates of linezolid
resistance.32-35 A recent study36 reported a linezolid resistance rate of 30.2% among
E. faecalis urine isolates, but was only 0.8% in our study. Linezolid resistance in
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enterococci has been linked with increasing linezolid use,37 highlighting the role of
antibiotic selective pressure and resulting changes in antibiotic resistance.

E. faecalis and E. faecium susceptibility to ampicillin, linezolid, tetracycline,
and vancomycin, was relatively stable. Though some of these resistance trends were
statistically significant, the small changes in resistance may not be clinically relevant.
The spread of multi-resistant enterococci has been associated with the
selective antibiotic pressure in tertiary care institutions38 and patients with recurrent
health-care exposures, so future research should quantify the impact of changing
antibiotic pressure on antimicrobial resistance and clinical outcomes.

Our study findings may be useful for informing antimicrobial stewardship
programs, which play a key role in directing empiric therapy and raising awareness of
new problems with resistance, which in turn improves antimicrobial resistance39 and
healthcare costs40. However, there are limitations to this study. First, this is an
ecologic study of facility-level resistance. Individual patients could have contributed
multiple isolates over the study period.41 Second, antimicrobial resistance in certain
strains of enterococci may be attributed to prior use of antibiotics42 which could not be
studied due to the lack of patient-level data. Third, the generalizability of the study will
be limited to the New England VA population that consists mostly of older, white
males. Forth, aggregated microbiology trend data offer less detailed information than
active surveillance, although, they are adequate at estimating the prevalence of
resistance.43 Fifth, there may have been differences in enterococci resistance rates
across the 5 facilities. Lastly, our results are limited by the number of cultures taken
and the changes in the number of isolates tested against a specific antibiotic over the
study period. Small changes in resistance patterns in a large number of isolates
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(mostly urine), may not be clinically significant but were statistically significant.
Conversely, larger changes in resistance in blood isolates were not statistically
significant due to a small number of isolates, but the changes may be clinically
important.

In conclusion, despite concerns surrounding VRE outbreaks multi-drug
resistance that makes the Enterococcus difficult to treat,2 we found stable
vancomycin resistance in Enterococcus among VA Medical Centers in New England.
Similarly, Enterococcus resistance was stable for other common treatments.
Additionally, daptomycin resistance did not emerge over the study period and
gentamicin resistance decreased.
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Appendix
Fig 1: Trends in E. faecalis resistance (2003-2015) for blood and urine
cultures
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Fig 2: Trends in E. faecium resistance (2003-2015) for blood and urine
cultures
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2.1 Abstract
Background: Several meta-analyses and observational studies have reported
improved clinical outcomes in patients with inflammatory conditions among users of
statins.
Objectives: To evaluate the impact of statin exposure on clinical outcomes in
bacteremic patients.
Methods: A retrospective cohort study was conducted using Optum ClinformaticsTM
with matched Premier Hospital data to assess inpatient mortality and length of stay
(LOS) among statin-exposed vs. non-exposed bacteremic patients hospitalized
between April 2010-March 2013. Patients who received at least two consecutive days
of antibiotic therapy within the first three days of hospital admission were included. In
the primary analysis, only incident statin users were included to avoid the "healthy
user" bias. Non-users were defined as patients without any pharmacy records for
statins. Cox proportional hazards regression models, adjusted by propensity scores,
were developed to evaluate the effect of statins on clinical outcomes. Secondary
analyses were conducted among existing statin users.
Results: Our study included 112 incident statin users and 1,597 non-users. Inpatient
mortality in bacteremic patients was non-significantly lower among statin users
compared to non-users (adjusted hazard ratio [HR] 0.45, 95% confidence interval [CI]
0.18-1.16). Reduction in inpatient mortality was significant among existing statin
users with at least 90 days of continuous therapy prior to admission, who continued
statin therapy during the admission (n=232, HR 0.37, 95% CI 0.14-0.96), and was
non-significant among existing users not continuing statin therapy during the
admission (n=401, HR 1.12, 95% CI 0.75-1.86). LOS was similar between all groups.
Conclusion: Our retrospective cohort study observed lower mortality for incident
users and existing users continuing statin use during admission. Though non-
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significant in incident users, the point estimate was similar to that observed in other
studies.
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2.2 Introduction
Bloodstream infections are the sixth most common principal reason for
hospitalization, accounting for 836,000 hospital stays in 2009.1 Moreover, it is the
most expensive cause of hospitalization in the United States (U.S.), accruing almost
$15.4 billion in collective hospital costs in 2009.1 Statins, inhibitors of 3-hydroxy-3methylglutaryl-coenzyme A reductase, decreases cardiovascular events among
patients with elevated cholesterol.2 Protective effects with statins have been observed
in inflammatory conditions, such as bacteremia3-6, sepsis7-9, pneumonia, and other
infections in terms of 30-day, 90-day, in-hospital, and long-term (>1 year) mortality
reductions, and these protective effects have been most pronounced in bacteremic
patients.10

The specific mechanism by which mortality is reduced among patients with
bacteremic infections remains undefined. A proposed mechanism has been the
moderation of the overall inflammatory response.11 Other previously observed antiinflammatory effects with statins have included lowering of C-reactive protein (CRP),
chemokine release (MCP-1, RANTES), cytokines (IL-1β, TNF α, IL-6, IL-8), and
adhesion molecules (P-selectin, VLA 4, CD11a, CD11b, CD18).12,13 Statins may also
have a direct antimicrobial effect14, and possible antibacterial activity of statins
against a variety of pathogens may be attributed to their ability to suppress cell
growth, and to promote apoptosis.15-17 In murine models, statin treatment inhibits
apoptosis in sepsis18, reduces nitric oxide overproduction19, regresses the endotoxic
shock induced damaged vascular responsiveness19, and also improves survival as it
maintains cardiac function and hemodynamic status after an onset of sepsis.20 A
randomized double-blind placebo-controlled trial among patients with acute bacterial
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infections found a significant reduction in the levels of inflammatory cytokines among
statin users.21

A number of meta-analyses10,22 and observational studies4-6,23 have reported
survival benefits among bacteremic patients exposed to statins compared to those
not exposed to statins. However, published research has not reached a consensus
on this association as several studies failed to observe significant results24,25 and/or
result estimates varied considerably.4,5,23,25 Optimal statin use duration required to
provide mortality benefits is still unknown, but the continuation of statin use during
hospital admission has been found to offer pronounced effects on survival.4

Differences between statin users and non-users in previous studies have
varied by data source6,22, study designs10,22-25 and sample size of the statin user
group.4,5,23 Observational studies evaluating this association have evident differences
in statin user and non-user group, potentially causing confounding of the exposureoutcome relationship.4,5,23 Many hospital based studies evaluating protective effects of
statins did not have information about medical history or medication use prior to the
admission.23,25,26 Therefore, this study aimed to determine whether the association
between statins and better clinical outcomes was observed among a privately insured
population with administrative data linked to hospital data. The primary objective of
this study was to evaluate the impact of incident statin use, and secondarily existing
statin exposures, on clinical outcomes, including inpatient mortality and length of
hospital stay, in bacteremic patients exposed to statins versus those not exposed to
statins in a large real-world clinical setting.
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2.3 Methods
2.3.1 Research Design and Methodology
A retrospective cohort study design was used to assess two different
outcomes, inpatient mortality and length of hospital stay, among statin-exposed vs.
non-exposed patients. A retrospective cohort study design was used because it
allows the comparison of individuals with differing exposures, which can be observed
in order to determine the health effects of the exposure over a period of time.27

2.3.2 Data Sources
This study was conducted using deindentified Optum ClinformaticsTM
(OptumInsight, Eden Prairie, MN) with matched Premier Hospital data (10/01/200903/31/2013), which is an administrative claims database from a large commercial
health plan (Optum ClinformaticsTM) matched with hospital data (Premier).

2.3.3 Study Population
Included in the analysis were adult patients (>18 years) having a primary
diagnosis for bacteremia or septicemia (International Classification of Diseases, 9th
Revision, Clinical Modification [ICD-9-CM] codes 003.1, 020.2, 022.3, 036.2, 038.0,
038.1, 038.10-038.12, 038.19, 038.2, 038.3, 038.40-038.44, 038.49, 038.8, 038.9,
054.5, 449, 771.81, 995.91, 995.92, 790.7) caused by any organism during the study
period.28 We only included patients with hospital admissions between 04/1/2010 and
03/31/2013, to allow for a continuous enrollment period of 6 months prior to
admission (Figure 1). Antibiotic therapy for each patient during the hospital stay was
assessed. Patients who received at least two consecutive days of at least one
antibiotic therapy for bacteremia29-32 within the first three days of the admission were
included. For patients with multiple admissions for bacteremia, only the first
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admission was included. Medication use was identified from both outpatient
prescriptions and medications given during the hospital stay.

2.3.4 Definition of Statin Use
For the primary analysis, we identified incident statin users, which was defined
as those initiating a statin (i.e., atorvastatin, cerivastatin, lovastatin, pravastatin,
rosuvastatin and simvastatin) within 90 days of hospital admission, or during the
hospitalization, after having not used statins in the three months prior to the initial
pharmacy record. A one-day gap in therapy was allowed, including separate one-day
gaps on several different occasions. Non-users were patients without any pharmacy
records for statins from the study start period through hospital discharge. The date of
the hospital admission was defined as the index date.

Secondary analyses were conducted among existing statins users. These
analyses were conducted separately among patients who, irrespective of their statin
initiation time, had at least a continuous 90-day exposure for statins prior to
hospitalization and did not continue during admission (existing, outpatient-only users),
and among patients who had a continuous statin exposure for at least 90 days prior
to hospitalization and continued statins for at least the first 5 days after hospitalization
(existing-continuous users). These existing statin users were compared with nonusers to assess differences in the outcomes.

2.3.5 Outcomes
The primary outcome of interest in this analysis was inpatient mortality. The
secondary endpoint that we evaluated was hospital length of stay. Inpatient mortality
was defined as death occurring during the hospital stay. The length of hospital stay
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was calculated as the number of days between hospital admission and the hospital
discharge date. For the length of stay, patients who died during the admission were
excluded from the analysis.

2.3.6 Statistical Analysis
To identify baseline differences between the exposed and non-exposed
groups, we analyzed demographic and clinical data including current and prior
comorbidities.28 For categorical variables, if the assumptions for the chi-squared test
were not met (expected count of 75% of cells >5), the Fisher's exact test was utilized.
For continuous variables, the t-test was used for normally distributed data, and the
non-parametric Wilcoxon Rank Sum test was used if the normality assumption of ttest was violated as assessed graphically and the Shapiro-Wilk test for normality.

The propensity score is the probability of treatment assignment conditional on
observed baseline characteristics, derived from the inclusion of various demographic,
hospitalization-related, and clinical characteristics in a logistic regression model. The
propensity score attempts to mimic a randomized controlled trial (RCT) by balancing
the exposure groups on observed baseline characteristics.33,34 In this study, the
propensity score was the predicted probability of statin use, as calculated from the
baseline covariates included in an unconditional logistic regression model which was
built with manual backward elimination.34-37 The model included type of statin, other
inpatient and outpatient medication use, such as calcium channel blockers,
angiotensin-converting enzyme inhibitors, and diuretics. Further, we included type of
antibiotic as differences in antibiotic therapy could have a large influence on
bacteremic mortality. The propensity score model also controlled for various
pathogens, where available, and comorbidities such as metabolic syndromes, HIV,
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cancer, and liver cirrhosis38. Initially, likelihood ratio tests were conducted on all
independent variables individually and variables with a p-value <0.25 were
considered as a candidate for inclusion in the multivariable model. Variables with a pvalue ≥0.05 were removed one at a time using backward elimination to determine the
final propensity score model. We assessed multicollinearity among independent
variables by review of correlation matrices and confirmed that all variance inflation
factor (VIF) values were <3.39 Further, we t assessed goodness of fit with the
Hosmer-Lemeshow goodness-of-fit test,39 and plotted propensity scores to review the
overlap of propensity score between groups. Patients from the statin user and nonuser groups were stratified by propensity score quintile to achieve homogeneity
between exposure groups within quintiles of the predicted probability of statin use.39
Covariate balance within propensity score quintiles was reviewed.35,36 The general
propensity score equation is illustrated below, where T is a binary treatment, Y is an
outcome, and X are background variables: p

). The final

propensity score model equations are included as footnotes in the results table.

Propensity score-adjusted Cox proportional hazards regression models were
used to assess the impact of statin use on time to occurrence of inpatient mortality
and the hazard ratios and 95% confidence intervals were calculated. We checked
Cox proportional hazards models for non-informative censoring and proportionality
using graphical displays, as well as the Supremum test.40 A PS-adjusted Cox
proportional hazards model offers an estimate of the impact of treatment on survival
after adjustment for variables which predict exposure. A hazard ratio greater than 1
for inpatient mortality (dependent variable) means that the hazard is higher in the
statin-exposed patients, and therefore the prognosis worse. On the other hand, a
hazard ratio <1 implies a better prognosis for statin users. The general form of the
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Cox proportional hazards model is: h(t|X) = h(t) exp(X1β1 + · · · + Xpβp). To evaluate
the association of statin use and in-hospital mortality, without accounting for the rate
at which deaths occur (time to event), we also computed the odds of inpatient
mortality in statin users versus non-users using conditional logistic regression model,
adjusting for PS quintiles. To assess the differences in length of stay between statin
users and non-users, we developed a PS-adjusted Poisson regression model with log
link.

The secondary analyses performed among existing statin users assumed the
proximity of statin-exposure to the admission, regardless of previous duration, could
offer protective effects. Separate propensity models were developed and used to
adjust Cox-proportional hazards models. These models were used to study the
survival benefits of existing, outpatient-only, as well as existing, continuous statin use.
For all analyses, statistical significance was considered a p-value of ≤0.05. All
statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).
This study was reviewed and approved as exempt by the University of Rhode Island’s
Institutional Review Board.

2.4 Results
For the primary analysis, we identified 1,709 patients who met our inclusion
and exclusion criteria (see Figure 2). This included 112 new initiators of statin use
and 1,597 non-users. Among statin users, 53 (47%) initiated statin in the 90 days
prior to admission and 59 (53%) anytime after admission. Of those initiating prior to
admission, 33 (62%) continued statin therapy. The results of the descriptive analyses
indicated that the cohorts differed with respect to baseline demographic and clinical
characteristics. Among statin users vs. non-users (Table 1), significant (p<.01)
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differences in age (median 61 vs. 53 years) and gender (39% vs. 53% females) were
observed. The median Charlson comorbidity index (CCI) was significantly higher for
statin users than non-users during the admission (2.7 vs. 2.1, p<0.0001; table 2) and
also during the 6 months prior to admission (4.0 vs. 2.7, p<0. 0001). Admission from
the emergency room occurred for 91% statin users and 96% non-users (p=0.01).
Marital status, race, region, and admitting physician specialty were similar between
statin users and non-users. Simvastatin (54.5%) and atorvastatin (28.6%) were the
most commonly used statins. Inpatient mortality among statin users was nonsignificantly lower (4.46% vs. 7.07%, p=0.4375) and LOS was higher (median 8.0,
interquartile range [IQR] 3.5-10.0 vs. 7.3 days, IQR 3.0-9.0], p=0.052) compared to
non-users. The crude absolute risk reduction (ARR) with statin use was 2.6%.
Variables that differed significantly, no longer differed within PS quintiles. The final PS
model c-statistic was 0.92, suggesting a strong model for predicting the probability of
statin use.37

The PS-adjusted Cox proportional hazards regression model evaluating time
to inpatient mortality demonstrated non-significantly lower inpatient mortality among
bacteremic statin users (hazard ratio [HR] 0.45, 95% CI 0.18-1.16; Table 3). In the
unadjusted analysis, the statin users had lower mortality rates than non-users (HR
0.56, 95% CI 0.23-1.38), despite being older and having more comorbidities. After
PS-adjustment, however, the inpatient mortality rates were slightly lower among statin
users. Length of hospital stay in statin users and non-users (median 6.0, IQR 3.-10.0
vs. 5.0 days, IQR 3.0-9.0, p=0.0821) was similar in adjusted analyses. In secondary
analyses, we identified 401 existing statin users with only outpatient statin use. After
PS-adjustment, we observed similar inpatient mortality among existing, outpatient
only statin users (HR 1.12, 95% CI 0.75-1.86) vs. non-users. However, survival was
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significantly higher in existing-continuous users (n=232, HR 0.37, 95% CI 0.14-0.96)
compared to non-users. Statin users had non-significantly lower odds of inpatient
mortality than non-users (odds ratio [OR] 0.44, 95% CI 0.14-1.44).

2.5 Discussion
In the primary analysis of this retrospective cohort study among privately
insured patients with bacteremia, the difference in inpatient mortality among incident
statin users compared to non-users was not significant, although the point estimate
(OR 0.44) was similar to a meta-analysis published in 2010.22 This meta-analysis
reported a 51% lower risk of mortality (OR 0.49, 95% CI 0.37-0.61) among patients
with bacteremia, pneumonia, or sepsis, and 67% lower bacteremia-related mortality
(evaluated in 4 studies out of 20, pooled OR 0.33, 95% CI 0.09-0.75) in statin users
compared to non-statin users.22 In our study, statin users were significantly older and
had a higher comorbidity burden compared to non-users, as observed in a previous
study41 evaluating protective effects of statins in inflammatory conditions.

In our secondary analyses, we observed higher survival among existingcontinuous users. The magnitude of association for this analysis (63% lower
mortality) was similar to a meta-analysis from 2012 that detected protective effects
with statin use (62% lower mortality) against infection-related death in the 9 studies
that focused on severe bacteremia (pooled OR 0.38, 95% CI 0.15–1.01), though
these findings were also non-significant.10 This meta-analysis also observed a 29%
decreased risk of all-cause mortality in patients with any type of infection (pooled OR
0.71, 95% CI 0.64-0.78).10 These results suggest better clinical outcomes among
statin users with infections. However, several of the studies included in the meta-
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analysis were subject to healthy user effects, by including existing statin users, and
may not represent the true association between statin use and mortality.47-49,64

Our findings for existing, outpatient-only statin use are consistent with the
results of two other meta-analyses that observed similar mortality rates among
bacteremic patients with statin use vs. non-use. The first meta-analysis of 4
randomized trials (1,818 patients) evaluating statin use in critically ill patients with
severe sepsis did not observe a significant reduction compared to placebo in 28-day
(risk ratio [RR] 0.95, 95% CI 0.72-1.27) and 60-day (RR 0.93, 95% CI 0.72-1.20)
mortality rates.24 In the other meta-analysis of 7 randomized trials comprising 1,720
patients, there was no difference in 28-day mortality (statin vs. placebo RR 0.93,
95% CI 0.46-1.89).42 The risk of mortality was similar between the statin and placebo
groups in the aforementioned meta-analyses, which may be attributed to the inclusion
of critically-ill patients with severe sepsis24, short statin therapy durations (14-28
days),24,42 or stoppage of statin therapy during the crucial period of inflammation and
hospital admission.42

The continuation of statin use during hospital admission was found to offer a
greater benefit, in terms of inpatient mortality. Similar results have been observed in a
retrospective cohort study.4 Additionally, a recent RCT reported a significantly lower
28-day mortality rate (5% vs. 28%; P=0.01) in the subgroup of existing-continuous
statin users.43 These results support continuing statins through the period of
inflammation, as the inflammatory response has been found to be lower among
patients on statins at the same time as they developed an infection.44,45
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Additional limitations of a number of the studies included in the
aforementioned meta-analyses were (a) control for few confounders23,5,8,11,25, (b) lack
of information about pre-hospitalization medication use23,25,26, (c) combined incident
and existing statin use8,11,26, and (d) combined pre-hospital and post-hospital use.26,46
These limitations may explain the conflicting findings between studies in regards to
the impact of statin use on mortality among patients with infections.

Well-designed RCTs can overcome these limitations. Several RCTs have
evaluated the anti-inflammatory or immunomodulatory effects of statins, including the
ASEPSIS trial (EUCTR2005-004636-52), which investigated the difference in rates of
sepsis converting to severe sepsis and of critical care admissions between statintreatment and placebo groups, and found the acute administration of atorvastatin in
patients with sepsis may prevent sepsis progression.47 The “Statin Therapy in the
Treatment of Sepsis” trial (NCT00676897), found significantly lower coenzyme Q10
levels, which may be associated with the inflammatory cascade in septic shock, in
septic shock patients compared to healthy controls.48 The “Statin for
Immunomudulation in Sepsis” trial (NCT00452608) and “Effect of Atorvastatin on the
Frequency of Ventilator-associated Pneumonia in Patients with Ischemic Stroke” trials
(NCT01550419), evaluated if atorvastatin can improve inflammation in septic patients
and if early use of statin (40mg oral atorvastatin during admission) prevents infections
such as ventilator-associated pneumonia (VAP), respectively. The results of these
trials are not yet available.

The effects of statin exposure on bacteremic mortality has been assessed
more frequently than other clinical outcomes, including hospital and intensive care
length of stay (LOS). According to the National Center for Healthcare Statistics
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(NCHS), hospitalization rates for septicemia or sepsis more than doubled from 2000
through 2008 and the average LOS was 75% longer than those hospitalized for other
conditions.49 To our knowledge, only one study has explored the association of statin
use with LOS, and found non-significant results for hospital (β = -0.8 days, 95% CI 2.2-1.7 days) or intensive care unit LOS (β = -0.1 days, 95% CI -3.7 to 3.8 days)
length of stay.25

The present study has several strengths. Firstly, we used administrative data
from a major private insurer linked to hospital data which allowed us to evaluate
medical history, previous medication use, as well as conditions present during the
admission and all medication exposures during the hospitalization. Secondly, we
attempted to account for "healthy user bias” by including incident statin users in our
primary analysis since patients taking preventive medications, such as statins, are
more likely to engage in healthy behaviors leading to favorable health outcomes
compared to non-statin users.50,51 Additionally, patients taking preventive medications
have a higher probability of being up-to-date with immunizations and having quit
smoking, and are less likely to have been admitted to a nursing home or need
advanced medical care.52 Third, we balanced baseline characteristics between statin
users and non-users that were significantly different using PS methods in an effort to
control for confounding. Lastly, to account for possible biases in socioeconomic and
health behaviors,53 we included demographic and clinical characteristics in the PS
models.

2.6 Limitations
The results of this study have potential limitations. We could not study the
protective effects of each statin separately due to small numbers. The effect of statins
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on inpatient mortality in patients with sepsis may be different for individual statins.54
We also could not assess dose-dependent effects, changes in statin therapy (drug or
dose) prior to admission, at admission, or during the admission, or the effects of
adherence due low sample sizes. In our review of statin doses, dispensing quantity in
incident users mostly reflected moderate to high doses. As we used an administrative
claims database for our analysis, we assumed outpatient statin exposure to be
equivalent to filling a prescription. In the primary analysis, our definition of incident
statin use was broad due to small numbers and included patients initiating prior to
admission or after admission, and also included those not continuing statins during
the admission (38%). As such, we could not evaluate the association using more
specific definitions of incident statin use.

Furthermore, there is a possibility of statins having a different impact on clinical
outcomes based on the causative pathogen, since the mechanism of action is not
exactly known and it may vary for different pathogens. Microbiology data was not
available for potential causative pathogen, but we identified organisms using ICD-9
codes, where available. Bacteremic treatment varies by organism type and we were
only able to use general inclusion criteria of having received an antibiotic which may
be used for bacteremia.29-32 Since we only evaluated a general bacteremic
population, our results may not be generalized to pathogen-specific bacteremias. As
such, patients without appropriate initial antibiotic treatment may have been included.
Despite using propensity scores to control for confounding, we could not control for
unmeasured confounding. We also could not differentiate bacteremic severity,
although we included ventilation status and sepsis proxies using diagnosis-related
groups (DRG).
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2.7 Conclusions
In conclusion, our retrospective cohort study quantified the effect of both
incident and existing statin use on clinical outcomes such as inpatient mortality and
hospital length of stay among bacteremic patients in a real-world clinical population.
Result estimates for incident and existing-continuous statin use, although nonsignificant for incident users, were similar to previous meta-analyses that observed
reductions in inpatient mortality after statin use among bacteremic patients. Further
unaddressed questions related to this research question include appropriate statin
exposure time and duration needed for maximum clinical benefits, and differences in
the magnitude of each statin's protective effects. Future studies should control for
healthy-user bias and differences in baseline characteristics between statin-users and
non-users.
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AppendixTable 1. Demographic and hospitalization-related characteristics in incident
statin users and non-users
Statin users

Non-users

(N=112)

(N=1,597)

Characteristics
Age (years, median and
IQR)

61

53-69.5

53

41-62

P-value
<.0001

Gender
0.0036
Female
44
39.3
854
53.48
Male
68
60.7
743
46.52
Race
Black
10
8.9
167
10.5
0.8371
Other
18
16.0
270
16.9
White
84
75.0
1160
72.6
Census region
East North Central
19
17.0
256
16.0
East South Central
5
4.5
38
2.4
Middle Atlantic
8
7.1
80
5.0
Mountain
8
7.1
166
10.4
0.4675
New England
<5
1.8
15
0.9
Pacific
7
6.3
157
9.8
South Atlantic
39
34.8
505
31.6
West North Central
12
10.7
149
9.3
West South Central
12
10.7
231
14.5
Admission Type
0.0116
Emergency
102
91.1
1534
96.1
Non-emergency
10
8.9
63
3.9
Admitting Physician Facility
ICU/Surgery
<5
3.6
68
4.3
0.5655
Medicine
42
37.5
671
42.0
Other
66
58.9
858
53.7
Diagnosis-related group (DRG) description
0.0867
Non-ventilation
101
90.2
1504
94.2
Ventilation
11
9.8
93
5.8
Hospital admission year
2010
37
33.0
385
24.1
0.1765
2011
38
33.9
572
35.8
2012
37
33.0
640
40.1
Data are median and interquartile range (IQR) or number and percent of patients.
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Table 2. Clinical characteristics and health service utilization in incident statin
users and non-users
Statin-users

Non-users

(n=112)

(n=1,597)

Characteristics

P-value

Comorbidities (during admission)
Charlson score (median and
IQR)

2

1-4

1

0-3

<.0001

2

1-4

1

0-3

<.0001

14
38
46
17
6
35
26
35
24
16
43

12.5
33.9
41.1
15.2
5.4
31.23
23.2
31.3
21.4
14.3
38.4

114
344
136
95
33
348
209
348
208
61
251

7.1
21.5
8.5
6.0
2.1
21.78
13.1
21.8
13.0
3.8
15.7

0.0399
0.0023
<.0001
0.0001
0.0381*
0.0201
0.0026
0.0201
0.0120
<.0001*
<.0001

Dyslipidemia including
hyperlipidemia

57

50.9

167

10.5

<.0001

Cellulitis or abscess

24

21.4

210

13.2

0.0136

Coronary atherosclerosis &
other heart diseases
Congestive heart failure
Esophageal disorder
Chronic kidney disease
Other liver disease
Acute myocardial infarction
Methicillin-resistant

44

39.3

118

7.4

<.0001

27
24
26
8
11

24.1
21.4
23.2
7.1
9.8

149
214
197
276
34

9.3
13.4
12.3
17.3
2.1

<.0001
0.0175
0.0009
0.0054
<.0001*

11

9.8

69

4.3

0.0168*

11
26

9.8
23.2

86
261

5.4
16.3

0.0496
0.0327*

13

11.6

55

3.4

0.0005*

10

8.9

53

3.3

0.0065*

Elixhauser score (median and
IQR)
Amputation
Cardiac arrhythmia
Coronary heart disease
Chronic ulcer
Coma stupor and brain
Chronic pulmonary disease
Chronic renal disease
Chronic respiratory disease
Depression
Diabetes complicated
Diabetes uncomplicated

staphylococcus aureus
Myocarditis
Other circulatory disease
Peripheral and visceral
atherosclerosis
Hyperplasia of prostate
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Skin or subcutaneous tissue
32
28.6
291
Peripheral vascular disease
13
11.6
46
Renal failure
61
54.5
615
Medication use (during admission)
Anti-hypertensive medication
90
80.4
850
Diabetic medication
91
81.2
993
Comorbidities (6 months prior)
Charlson score (median and
3
1-6
1
IQR)
Elixhauser score (median and
3
2-6
2
IQR)
History of cardiac arrhythmia
36
32.1
299
History of coronary heart
45
40.2
122
History of chronic ulcer
17
15.2
96
History of chronic pulmonary
36
32.1
327
History of chronic renal
27
24.1
169
History of chronic respiratory
36
32.1
327
History of dyslipidemia
59
52.9
244
including hyperlipidemia

18.2
2.9
38.5

0.0119*
<.0001*
0.0008

53.2
62.2

<.0001
0.0075

0-3

<.0001

0-4

<.0001

18.7
7.6
6.0
20.5
10.6
20.5

0.0006
<.0001
0.0002
0.0035
<.0001
0.0035

15.3

<.0001

History of deficiency and other
anemia

39

34.8

392

24.6

0.0153

History of coronary
atherosclerosis diseases

42

37.5

106

6.6

<.0001

History of acute
cerebrovascular disease

15

13.4

46

2.9

<.0001*

31

27.7

145

9.1

<.0001

<5

2.7

9

0.6

0.0390*

5

4.5

11

0.7

0.0027*

35

31.3

167

10.5

<.0001

58

51.8

347

21.7

<.0001

19
.

17.0
.

136
69

8.5
4.3

0.0026
0.0208*

22

19.6

131

8.2

<.0001

7
22

6.3
19.6

32
147

2.0
9.2

0.0131*
0.0003

History of congestive heart
History of crushing or internal
injury
History of disorders diagnosed
for non-adults
History of diabetes w/
complication
History of diabetes w/o
complication
History of heart valve disorder
History of hepatitis
History of hypertension w/
complication
History of infective arthritis
History of chronic kidney

41

History of later effects of
7
6.3
39
cerebrovascular disease
History of other diseases of
11
9.8
84
History of malaise and fatigue
34
30.4
315
History of acute myocardial
11
9.8
16
infarction
History of myocarditis
16
14.3
70
History of occlusion or stenosis
5
4.5
25
History of other endocrine
13
11.6
84
History of other & ill-defined
9
8.0
22
cerebrovascular diseases
History of other & ill-defined
14
12.5
89
heart diseases
History of peripheral and
18
16.1
85
visceral atherosclerosis
History of skin or
30
26.8
296
subcutaneous tissue infections
History of open wounds of
11
9.8
51
extremities
History of mild liver disease
5
4.5
175
History of peripheral vascular
19
17.0
102
disease
History of renal failure
31
27.7
262
History of valvular disease
18
16.1
124
Medication use history (6 months prior)

2.4

0.0272*

5.3
19.7

0.0415
0.0069

1.0

<.0001*

4.4
1.6
5.3

<.0001*
0.0421*
0.0050

1.4

<.0001*

5.6

0.0029

5.3

<.0001

18.5

0.0314

3.2

0.0017*

11.0

0.0258*

6.4

<.0001

16.4
7.8

0.0022
0.0021

Diabetic medication
38
34.0
554
34.7
0.1903
Data are median and interquartile range (IQR) or number and percent of patients.
*Values calculated using Fisher's Exact test

Table 3. Clinical outcomes in statin users vs. non-users
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HR (95% CI)

No. of events/No. of patients
Incident statin
users2
5/112
Existing outpatient
statin users3

Non-users

Unadjusted

113/1,597

0.56 (0.23 - 1.38)

Propensity
Adjusted1)
0.45 (0.18- 1.16)

Non-users

44/401
113/1,597
1.57 (1.11-2.23)
Existing outpatient
statin users
Non-users
continuing statin
use4
6/232
113/1,597
0.34 (0.15-0.76)
HR=hazard ratio; CI=confidence interval.

1.12 (0.75-1.86)

0.37 (0.14-0.96)

1)

Adjusted by propensity score quintiles (reference quintile I).

2)

The final PS model equation for predicting incident statin exposure.
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3)

The final PS model equation for predicting existing, outpatient-only statin exposure.

4)

The final PS model equation for predicting existing- continuous statin exposure.

In the above equations, y is the probability of receiving a statin, α is the intercept, β’s
are the coefficients on the independent variables and ε is standard error.
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Figure 1. Study timeline for patient selection
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Figure 2: Study cohort identification
Premier data (n=25,649)

Exclusions:
Missing medical record or not
eligible for 6 months before
hospital admission (N=5,647)
Non-adults and patients
without primary bacteremic
diagnosis (n=17,016)

Adult (≥18 years) inpatients with
primary diagnosis of bacteremia
(n=2,986)

Patients receiving any antibiotic within
2 days of hospital admission
(n=2,695)

Exclusions:
No antibiotic treatment within
2 days of hospital admission
(n=291)

Exclusions:
Other statin use not listed
below (n=353)

Incident statinusers
n=112
Initiated statin in
the 90 days prior
to the hospital
admission or
during the
admission

Existing,
outpatient-only
statin-users
n=401
At least 90 days
of statin use prior
to the hospital
admission and did
not continue
during the
admission

Existing
continuous statinusers
n=232
At least 90 days
of statin use prior
to the hospital
admission and
continued at least
first 5 days during
the admission
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Non-users
n=1,597
No statin use in 6
months prior to
the hospital
admission or
during the
admission

Figure 3: Adjusted proportional hazards among incident statin users vs. nonusers

Note- On the x-axis, 'tmdc' represents "time to death".
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3.1 Abstract
Background: There is no consensus as to whether statin therapy should be
continued among patients presenting to the hospital with bacteremia, and if so, what
duration would be associated with better survival.

Objectives: To identify a statin therapy duration that would decrease mortality in
bacteremic statin users.
Methods: Using Optum ClinformaticsTM with matched Premier hospital data
(08/2009-03/2013), we conducted a case-control study among bacteremic statin
users. Cases who died during the hospitalization were matched 1:1 to survivors on
disease risk scores. Duration of statin therapy during the admission was evaluated in
patients with at 3 months of pre-admission statin use. Classification and regression
tree (CART) analysis was conducted to identify the optimal continued statin use
duration which provided the lowest inpatient mortality, and logistic regression was
used to calculate the odds of mortality associated with the duration identified in the
CART analysis.
Results: We included 58 disease risk score matched pairs of cases and controls.
Forty-one percent (n=47) of patients continued statin therapy during the hospital
admission, of whom 15 (32%) were cases and 32 (68%) were controls. The CART
analysis partitioned the continuation of statin therapy at 1.5 days, which predicted a
lower inpatient mortality rate among bacteremic patients with statin exposure higher
than this duration compared to those with lower duration, which included those not
continuing statin therapy during the admission (29% vs. 62%). The odds of inpatient
mortality for bacteremic patients with at least 2 days of continued statin use was
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significantly lower than those with less than 2 days of continued use (OR 0.24, 95%
CI 0.11-0.55).
Conclusion: Among matched pairs of cases and controls with statin use for at least
90 days prior to the admission, the continuation of statins during the admission for at
least 2 days demonstrated a survival benefit among bacteremic patients.
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3.2 Introduction

Bloodstream infections are the third most frequent hospital-wide infections in
the Unites States (U.S.), along-with pneumonia (both 11%), following urinary tract
infection (36%) and surgical site infection (20%).1 Between 2000 and 2009, inpatient
mortality among patients with principal diagnoses of bloodstream infections remained
high (16.7% and 16.3%, respectively).2 Evidence suggests that statins may improve
survival in patients with bacteremia3-6 and sepsis,7-9 including 14-day6, 15-day3, 31180 day,10 and all-cause hospital mortality4,8, as well as persistent bacteremia (PB).6
While numerous studies have found reduced mortality with statins in bacteremic
patients, statin duration and measurement of outcomes differ across these studies.3-5
As a result, rates of survival vary, particularly as statin exposure varies.4,10 Several
studies not only observed a decline in inpatient mortality after continuing statin use
during admission,4,10 but also an increase in mortality after cessation of statin
therapy.4,11 Since the length of statin treatment time varies between studies, there is
no consensus on the duration of statin continuation that would provide the maximum
advantage in terms of clinical outcomes.

While several meta-analyses12,13 and observational4-6,10 studies observed
protective effects with statins in bacteremia, one meta-analysis14 did not observe
improvements in clinical outcomes after statin use. However, this meta-analysis was
conducted among critically-ill patients with severe sepsis, and some of the included
studies only had short durations of statin use.4,5,10 Other studies with shorter statin
durations also did not demonstrate a statistically significant association between
statin use and mortality.10,14,15 A recent RCT evaluating benefits of continued statin
therapy on inflammatory parameters and sepsis among patients with pre-existing
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statin use16 did not find clinical benefits of continuation. As such, there is a lack of
evidence regarding the appropriate exposure duration needed for statins to provide
the utmost protective effects in bacteremic patients. The main objective of this study
was to identify a time breakpoint of statin continuation which minimized inpatient
mortality among bacteremic patients.

3.3 Methods
3.3.1 Research Design and Methodology
A case-control study design was used to estimate a time breakpoint in statin
continuation at which the highest clinical benefit would be seen in terms of survival
(i.e., lowest inpatient mortality). A case-control study is an analytical study that
compares individuals who have a specific outcome (cases) with a group of individuals
that do not have the outcome (controls). A case-control design was utilized because it
is the most effective study design for evaluating multiple exposures when an outcome
is rare.17

3.3.2 Data Sources
This study was conducted using deidentified Optum ClinformaticsTM
(OptumInsight, Eden Prairie, MN) with matched Premier hospital data (10/01/200903/31/2013) among adult (≥18 years) patients with a primary diagnosis of bacteremia
during a hospital admission. This dataset is an administrative claims database from a
large commercial health plan (Optum Clinformatics) matched with hospital data
(Premier).
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3.3.3 Study Population
Adult patients with continuous enrollment for at least six months in the
commercial health plan prior to hospital admission were included. Patients were
included if they were hospitalized between 04/01/2010 and 03/31/2013 with a primary
diagnosis of bacteremia or septicemia (International Classification of Diseases, 9th
Revision, Clinical Modification [ICD-9-CM] codes 003.1, 020.2, 022.3, 036.2, 038.0,
038.1, 038.10-038.12, 038.19, 038.2, 038.3, 038.40-038.44, 038.49, 038.8, 038.9,
054.5, 449, 771.81, 995.91, 995.92, 790.7)18 by any causative organism. We
excluded patients who, on the first three days after hospital admission, did not receive
a minimum of two successive days of at least one bacteremic antibiotic therapy.19-22
The index date was defined as the date of the first hospital admission during the
study period, and subsequent multiple hospital admissions were not considered for
the analysis. From this cohort, only patients with a minimum of 3 months of
continuous statin use in the 3 months prior to admission were selected for inclusion
(Figure 1).

3.3.4 Cases and controls
Cases included those who died during the admission. In a case-control study,
controls should be drawn from the same population from which cases are derived, in
order to reduce the chance that group differences account for the difference in the
exposure being evaluated.23 Thus, controls were selected from the same cohort of
adult patients who had a primary diagnosis of bacteremia on hospital admission and
received an antibiotic therapy, but experienced a different outcome (i.e., no inpatient
mortality). Controls were matched to cases on disease risk score (DRS).24 DRS is a
confounder summary method, commonly used in case-control studies to control for
confounding by calculating the predicated probability of an outcome in the absence of
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exposure.25,26 A recent simulation study27 suggested the DRS model could cause
higher bias due to misspecification at higher outcome incidences, however, when the
outcome is rare, DRS matching would increase the statistical efficiency of casecontrol studies. The DRS is considered a useful method in case-control studies,25
especially when the association between covariates and exposure is modest
(squared multiple correlation coefficient amid exposure and confounders <90%).28
The stratified DRS is a retrospective balancing score and therefore it works in a
similar manner in case-control studies as the propensity score works in cohort
studies.26

3.3.5 Statin duration
Among the patients with at least 90 days of statin therapy in the 90 days
before admission, the primary exposure of interest was the period of continued statin
use during admission. The statins included were atorvastatin, cerivastatin, fluvastatin,
lovastatin, pravastatin, rosuvastatin and simvastatin. Statin use duration was counted
as the number of days of statin use between initiation and the last pharmacy record
without more than one day gap in therapy. The period of continued statin use during
admission was considered to be an exposure among the patients having a similar,
minimum pre-admission statin use of at least 3 months. A one day gap in therapy was
allowed, but the gap was not counted in the calculation of the statin use period.

3.3.6 Statistical Analysis
Disease risk scores (DRS) were calculated to control for confounding. A DRS
is the probability of a patient having a particular outcome in the absence of the
exposure.24,25 Therefore, we calculated DRS as the probability of inpatient mortality
among unexposed patients, that is, statin users not continuing use post-admission.
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Using likelihood ratio tests, we compared each independent variable to the null
model. Variables with a p-value <0.25 in likelihood ratio tests were included in an
initial multivariate model and removed using a backward elimination approach, if the
p-value of the parameter estimate was less than 0.05 to arrive at the final DRS model.
The model was checked for multicollinearity using variance inflation factor (VIF) and
correlation matrices, and goodness of fit was checked using the Hosmer-Lemeshow
goodness-of-fit test.29,30 The final DRS model c-statistics was 0.91. The full DRS
model equation can be found in the footnote of the main results. Using nearest
neighbor matching within a caliper of 0.25 distance, a single control was selected for
each case.31 We checked DRS balance between cases and controls using graphical
displays (see figure 2).

To partition statin continuation days associated with the lowest risk of death
(i.e., highest survival), we conducted a classification and regression tree analysis
(CART).32,33 The CART analysis, which includes an optimal tree selection based on
pruning and cross-validation, identified subsets of patients at lowest risk of death and
determined the influence of statin exposure in these subsets of patients. The CART
method employs a recursive partitioning for building hierarchical binary classification
trees. The CART model fits a simple prediction model within each partition. Each
partition is binary, occurring on one explanatory variable at a time and at the point of
maximum heterogeneity of the two groups with regards to the dependent variable.
CART models are useful because of their non-parametric, non-linear structure.33 As a
result, they do not make any distribution assumptions, they treat the data generation
process as unknown, and they do not require a functional form for the predictors.
Indeed, tree methods are probably one of the most easily interpreted statistical
techniques; they are conceptually simple yet analytically powerful.33,34 In the CART
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analysis, the primary dependent variable was inpatient mortality (case/control) and
the independent variable was days of continued statin exposure during
admission. The trees were automatically developed to forecast inpatient mortality by
considering every possible cut-point on statin continuation duration at every node in
the classification tree. We checked the fitness of the tree by plotting cross-validated
error rate vs. size of a tree, and identified an appropriate complexity parameter
(CP).33,34 Based on the split provided by the CART analysis, conditional logistic
regression was conducted to calculate the odds of mortality. All statistical analyses
were conducted using either SAS version 9.4 (SAS Institute, Cary, NC) or R software
version 3.2.0 (The R Foundation for Statistical Computing) with a recursive
partitioning technique “rpart” package that was developed for Splus (Insightful
Corporation, Seattle, WA) by Therneau and Atkinson.35 This study was reviewed and
approved as exempt by the University of Rhode Island’s Institutional Review Board.

3.4 Results
During the three-year study period, 61 (6.9%) patients died and 821 (93.1%)
did not die during their hospital stay amongst the 882 patients with at least 3 months
of statin use in the 3 months before admission. Using DRS matching, 58 controls
were matched to 58 cases using nearest neighbor matching at a caliper distance of
0.25. Due to matching, baseline characteristics were very similar between cases and
controls in terms of age (median 68 vs. 67 years, p=0.8520; Table 1), gender (39.7%
vs. 43.1% females, p=0.7992), race (20.7% vs. 15.5% non-whites, p=0.7637), as well
as the Charlson comorbidity score during the admission (median=4 vs. 4, p=0.8239)
and in the six months prior to admission (median=4 vs. 4, p=0.4959; Table 2). The
length of hospital stay was significantly longer among controls compared to cases
(median=9 vs. 5 days, p=0.0005). Of the 47 (41%) patients who continued statin use
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during the hospital admission, 32% (n=15) were cases and 68% (n=32) were
controls. The average statin therapy duration continued during admission among
cases and controls was 1.5±3.7 vs. 4.5±7.5 days, respectively.
The CART analysis partitioned the dependent variable of statin therapy
duration, suggesting differences in inpatient mortality at different statin continuation
durations. See Fig. 3. The study included an equal number (n=58) of cases and
controls, producing a 50% survival rate at the root node. The split at 1.5 days
predicted patients with <2 days of continued-during-admission statin use (n=74, 64%)
have 62.2% probability of inpatient mortality (n=46 of 74), while the patients with ≥2
days of continued-during-admission statin use (n=42, 36%), have only 28.6% (n=12
of 42) chances of inpatient mortality. In other words, among bacteremic patients with
existing statin use, inpatient survival was higher among those continuing statins for at
least 2 days after the admission compared to those not continuing or with 1 day of
use (71.4% vs. 37.8%) and the odds of inpatient mortality was 76% lower (OR 0.24,
95% CI 0.11-0.55).
3.5 Discussion
In this DRS matched case-control study, we identified a specific continued
statin use duration threshold required to provide the maximum survival benefit among
bacteremic patients, which was the continuation of statin therapy for at least 2 days.
The 76% lower odds of inpatient mortality among statin users continuing use for at
least 2 days agreed with existing literature evaluating this association.4,5,10 A
retrospective cohort study among bacteremic patients found a reduced adjusted
hospital mortality rate (OR 0.39, 95% CI 0.17-0.91, p=0.029) in those taking statins
prior to admission, which decreased even further with the continuation of statin during
the admission (OR 0.06, 95% CI 0.01-0.44, p=0.0056).4 This study also observed
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similar finding in terms of deaths attributable to bacteremia in patients with statin use
only before admission (OR 0.29, 95% CI 0.10-0.86, p=0.025) versus continued during
admission (OR 0.09, 95% CI 0.01-0.64, p=0.016).

Another study5 conducted among bacteremic patients taking a statin at the
time of admission and continuing throughout the hospitalization at a Veterans Affairs
Medical Center in Washington, identified a therapeutic benefit with statin continuation
(adjusted OR 0.13, 95% CI 0.02–0.99). The aforementioned study included mostly
males (99.5%), while females made up 41% of our study population.

Our findings imply that the statin use is necessary during a crucial phase of
inflammation development, similar to previous studies36,37 observing a decline in
inflammatory response among patients developing infections while on statin therapy.
The extent of improvement in clinical outcomes after statin use among patients with
inflammatory disorders is still a dilemma, and the mechanisms of action due to which
statins provide clinical benefits remain unconfirmed. There are several possible
reasons why existing statin use at the time of inflammation, is necessary to observe
clinical benefits in bacteremic patients. Anti-inflammatory properties of statins have
been credited to their ability to reduce C-reactive protein (CRP) and cytokines (IL-6,
IL-8),38,39 and studies have demonstrated that the time required by statins to reduce
CRP varies, based on statin dose, patient disease,40 and type of statin41,42. For
example, pravastatin reduces CRP levels at 12 and 24 weeks,41 while simvastatin
could reduce CRP within 14 days.42 Further, low levels (<20 mg/dL) of high-density
lipoprotein (HDL) cholesterol) on the first day of severe sepsis was found to be
associated with an increase in mortality and adverse clinical outcomes.43
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Our results differed from the results of a meta-analysis12 that evaluated an
association between outpatient statin use and infectious disease-related mortality,
with pooled ORs of 0.62 (95% CI 0.534-0.72), 0.68 (95% CI 0.53-0.89), and 0.86
(95% CI 0.70-1.07) for 30-day, 90-day, and long-term (>1 year) mortality,
respectively. Our results may differ from this meta-analysis12 as we only included
bacteremia, while the meta-analysis included bacteremia, sepsis, pneumonia, and
other infections in outpatient settings. Additionally, the meta-analysis only evaluated
outpatient statin use prior to admission and continuation of statin use during
admission was unknown. Conversely, we investigated both statin use before
admission and continued during admission.

A recent propensity-score matched cohort study15 found non-significant
beneficial effects with statin use. However, the authors note that pre-admission
indications and statin therapy duration were not available. A recent RCT also did not
observe benefits of continued statin therapy on inflammatory parameters and sepsis
among existing statin users.16 However, this study has several methodological issues
as pointed out in a correspondence by Bostock et. al.,44 including a vague primary
endpoint, lack of information regarding previous statin therapy duration, and use of
the Mann-Whitney test to evaluate the matched groups.

Our study is a step forward in the direction of identifying an optimal statin
duration for inflammatory conditions. To the best of our knowledge, this is the first
study in a large, privately insured population in the U.S. evaluating an optimal
continued statin therapy duration among patients with inflammatory conditions. We
utilized a machine-learning analysis method, CART, that allowed us to identify an
exact statin therapy duration at which inpatient mortality was lowest among patients
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with bacteremia. Other factors may affect the impact of statin therapy on mortality,
including baseline differences in patient characteristics, differences in bacteremic
severity, regional differences in infections, statin prescription patterns, pre-admission
and post-admission comorbid conditions as well as medication use. However, we
used DRS to match controls to cases in order to account for confounding. The
strength of an observational study generally depends on the quality of the data
source. However, we utilized administrative data from a large, national insurer, which
is not affected by recall or surveillance bias. Further, used administrative and hospital
linked data from a real-world clinical population with health-coverage from a major
private payer.

Our study offers evidence regarding continuation of statin therapy in existing
statin users presenting to the hospital with bacteremia. Although our findings indicate
benefits with continuation of statins during admission, greater information is needed
regarding the risks of continuation, in terms of adverse events, to enable a clear
benefit-risk assessment. There is an ongoing controversy about the benefit-risk
assessment of statins in general ("statin wars")45 between editors of two English
medical journals, the British Medical Journal (BMJ) and Lancet. In 2014, the BMJ
published two papers claiming the side effects from statins are much higher than
reported in clinical trials, while statin trial leaders published a review identifying the
benefits of statins in the Lancet in 2016. Statins are life saving medications for many
patients with evaluated cholesterol and cardiovascular risks, however, for the
potential for adverse effects also exist, as with all medications. Despite the wellestablished benefits of statins in patients with cardiovascular diseases, statin side
effects, such as liver damage, diabetes mellitus, and muscle pain, may outweigh the
widely accepted benefits. Consequently, any future RCT evaluation of the association
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between statin use and clinical outcomes in bacteremic patients should include a
benefit-risk assessment.

3.6 Limitations
Our study has a few limitations. First, we were unable to assess adherence or
dose-dependent effects of statins that might affect bacteremic mortality. Depending
on the severity of the infection, different statin doses and different statins may be
used. While statin therapy may been continued more frequently in lower-risk patients,
as clinicians hear about the potential protective effects of statins, there may
channeling bias in the opposite direction, where more severe patients are kept on
their statin therapy.46 Second, our study relied on a claims database, which raises the
concern of misclassification due to coding errors throughout medical claims
processing. Further, use of this database assumed actual exposure from prescription
claims and hospital charges for medications. Third, we could not study differences in
mortality with statin continuation duration in bacteremia caused by specific
pathogens. A previous study26 observed greater protection with statins in S. aureus
bacteremia compared to bacteremia caused by Gram-negative bacilli, while also
suggesting greater survival in nosocomial versus community-associated
bacteremia.26 Our study could not evaluate these differences. Moreover, the sample
size of our study was small. Lastly, the limitations of CART analysis include an
inability to fully describe the observed data due to uncertainty that remains in the
prediction of the model and potential existence of multiple threshold values despite a
single “optimal” split.47
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3.7 Conclusions
In conclusion, this disease risk score matched case-control study conducted in
a real-world clinical population identified a time breakpoint of statin continuation which
maximized survival among bacteremic patients. Our results corroborate findings from
previous studies which indicate continuation of statins during the hospital admission
reduces mortality. The findings of our study are unique and add to the literature on
regarding the minimal duration of continued statin use.
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AppendixTable 1. Demographic and hospitalization-related characteristics in cases and
controls
Characteristics
Age (years)

Cases (n=58)

68

Controls (n=58)

61-77

67

Gender
Female
23
39.7
25
Male
35
60.3
33
Race
Non White
12
20.7
9
White
46
79.3
49
Admitting Physician Facility
ICU/Surgery
<5
3.4
<5
Medicine
18
31.0
16
Other
38
65.5
40
Diagnosis-related group (DRG) description
Non-Ventilation
47
81.0
48
Ventilation
11
19.0
10
Hospital admission year
2010
10
15.5
9
2011
18
37.6
21
2012
30
51.7
28
Comorbidities (during admission)

Charlson score
(during admission,
4
2-6
median and IQR)
Elixhauser score
(during admission,
6
4-8
median and IQR)
Comorbidities (6 months prior)
Charlson scoreHistory (6 months
4
2-8
prior, median and
IQR)
Elixhauser scoreHistory (6 months
5
2-8
prior, median and
IQR)

P-value

60-82

0.8520

43.1
56.9

0.7061

15.5
84.5

0.7637

3.4
27.6
69.0
82.8
17.2
15.5
36.2
48.3

4

2-7

6

5-8

4

1-7

5

2-8

0.9190

0.8095

0.9494

0.8239

0.2870

0.4959

0.8413

Data are median and interquartile range (IQR) or number and percent of patients.
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Figure 2: Case-control study design

Premier data (n=25,649)

Adult (≥18 years) inpatients with
primary diagnosis of bacteremia
(n=2,986)

Exclusions- Nonstatin users and
incident statin
users (patients
without at least 90
days of continuous
outpatient statin
use, one day gap
allowed) (n=1,813)

Patients receiving any antibiotic within 2
days of hospital admission (n=2,695)

Excluded1. Missing medical record or
not eligible- 6 months before
hospital admission (N=5,647)
2. Non-adults and patients
without primary bacteremic
diagnosis (n=17,016)

Exclusions:
No antibiotic treatment
within 2 days of hospital
admission (n=291)

Patients meeting inclusion criteria
(n=882)

Patients with inpatient
mortality (n=61)

Patients with no inpatient
mortality (n=821)

Matching on Disease Risk Scores

Controls (n=58)

Cases (n=58)

68

Figure 2: Disease risk scores distribution among cases and controls

Note: On the y-axis, 0 represent controls, while 1 represent cases.
On the x-axis, estimated probability is the disease risk score.
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Figure 3: CART model predicting inpatient mortality risk based on continued
during admission statin duration among patients with baseline pre-admission
statin use of 90 days.

Note: "in.days" represents "continued-during-admission statin therapy duration".
The study included an equal number (n=58) of cases and controls, producing a 50%
survival rate at the root node. The split at 1.5 days predicted patients with <2 days of
continued-during-admission statin use (n=74, 64%) have 62.2% probability of
inpatient mortality (n=46 of 74), while the patients with ≥2 days of continued-duringadmission statin use (n=42, 36%), have only 28.6% (n=12 of 42) chances of inpatient
mortality. In other words, among bacteremic patients with existing statin use, inpatient
survival was higher among those continuing statins for at least 2 days after the
admission compared to those not continuing or with 1 day of use (71.4% vs. 37.8%)
and. the odds of inpatient mortality was 76% lower (OR 0.24, 95% CI 0.11-0.55).
The final DRS model equation for predicting inpatient mortality developed in patients
not continuing statins during the admission.
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Here y is the probability of inpatient mortality, α is the intercept, β’s are the
coefficients on the independent variables and ε is standard error.
Figure 4: Cross-validated error rate vs. size of tree for analysis on statin users
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